STATES PATENT AND TRADEMARK OFFICE

9999999

88888

In re Applicant:

Iris PECKER, et al

Serial No.:

10/786,149

Filed:

February 26, 2004

Group Art Unit: 1644

For:

Heparanase Specific Molecular Probes and

Their Use in Research and

Attorney

Medical Applications

Docket: 27595

Examiner:

Marianne DiBrino

TERMINAL DISCLAIMER

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The owners, InSight Biopharmaceuticals Ltd., of Rabin Science Park, P.O. Box 2128, 76121 Rehovot, Israel, and Hadasit Medical Research Services and Development Ltd., of Kiryat Hadassah, 91120 Jerusalem, Israel, having 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,699,672. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

01/06/2005 JBRLINAN 00000109 10786149

01 FC:2814

65.00 OP

2

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Authorization to charge the above Terminal Disclaimer fee of \$65 to the Credit Card number listed on the attached Credit Card Payment Form PTO-2038 is attached herewith. In the event additional fees are required, please charge these additional fees to Deposit Account 50-1407. In the unlikely event payment by the Credit Card issuer is refused, please charge the Terminal Disclaimer fee of \$65 to Deposit Account 50-1407.

Respectfully submitted,

Sol Sheinbein

Registration No. 25,457

Date: December 23, 2004